Cited by 125Neurological disorders and treatmentsObsessive-Compulsive Spectrum DisordersTreatment of Major Depression

Deep brain stimulation of the medial forebrain bundle: Distinctive responses in resistant depression

Fenoy, Albert J., Schulz, Paul, Selvaraj, Sudhakar, Burrows, Christina, Spiker, Danielle, Cao, Bo, Zunta-Soares, Giovanna, Gajwani, Prashant +2 more·2016·Journal of Affective Disorders

Abstract

Background Treatment resistant depression (TRD) is a serious, disabling disease. Deep brain stimulation (DBS) to the superolateral branch of the medial forebrain bundle (MFB), as proposed by Schlaepfer et al. (2013), has led to rapid anti-depressant response but has not been replicated.Methods In this interim analysis of an ongoing pilot study of ten subjects, we assessed the efficacy of MFB-DBS in a cohort of four TRD patients over a 52-week period using the Montgomery-Åsberg Depression Rating Scale (MADRS) as the primary assessment tool. Implanted patients entered a 4-week single-blinded sham stimulation period prior to stimulation initiation. Deterministic fiber tracking analysis was performed to compare modulated fiber tracts between patients.Results Intraoperatively, responder patients displayed immediate increased signs of energy and motivation upon stimulation at target. There was no significant mean change in mood during sham stimulation phase. Three of 4 patients had >50% decrease in MADRS scores at 7 days post-stimulation initiation relative to baseline. One patient withdrew from study participation. At 26 weeks, two of 3 remaining patients continue to have >80% decrease in MADRS scores. One patient failed to have response; evaluation of modulated fiber tracts revealed reduced frontal connectivity to the target region.Limitations This is an interim report, with limited conclusions.Conclusion This study of MFB-DBS shows similar rapid anti-depressant effects within the first week of stimulation as initially reported by Schlaepfer et al. (2013). Implementation of anhedonia measurements would greatly augment characterization of the striking motivational effects observed. We urge others to pursue this target to further prove efficacy. ClinicalTrials.gov (identifier: NCT02046330) https://clinicaltrials.gov/ct2/show/NCT02046330.

Integrity signals

Registry

Crossref · 10.1016/j.jad.2016.05.064

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the open-label phase of the Fenoy et al. study, at 1 year the response rate was 66% and the remission rate was 50%.

    “at 1 year (RS: 66%, RM: 50%)”

    From Deep brain stimulation for depression. (2022) · cites this paper as [70]

  • In the Fenoy et al. single-blind phase, no significant difference was found between blinded on and off conditions.

    “Results do not indicate any significant difference between blinded on/off conditions”

    From Deep brain stimulation for depression. (2022) · cites this paper as [70]

  • In the open-label phase of the Fenoy et al. study, the response rate at 1 week of MFB DBS was 50%.

    “promising response and remission rates were observed at 1 week of MFB DBS (RS: 50%)”

    From Deep brain stimulation for depression. (2022) · cites this paper as [70]

Cites

Flagged first, then by citations

3 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Fenoy, A. J., Schulz, P., Selvaraj, S., Burrows, C., Spiker, D., Cao, B., Zunta-Soares, G., Gajwani, P., Quevedo, J., & Soares, J.
Affiliations
The University of Texas Health Science Center at Houston (US)
Corresponding author
Fenoy, Albert J.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2016-10
Volume
203
Pages
143-151
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2409297594
Cited by
125
References
44
Citations by year
2026: 1 · 2025: 8 · 2024: 13 · 2023: 13 · 2022: 17 · 2021: 22 · 2020: 11 · 2019: 9 · 2018: 19 · 2017: 12
FWCI
10.03
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Meyers Squibb
  • Forest Laboratories
  • Merck
  • Elan Pharmaceuticals
  • Dunn Foundation
Topics
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
deep brain stimulation, medial forebrain bundle, treatment-resistant depression, deterministic fiber tracking, anhedonia, motivation, sham stimulation
MeSH terms
Adult, Affect, Female, Humans, Male, Medial Forebrain Bundle, Middle Aged, Motivation, Pilot Projects, Treatment Outcome, Deep Brain Stimulation, Diffusion Tensor Imaging, Neuroimaging, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review